Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06474975

Intra-SURGerY High-resolution Specimen PET/CT Imager for Margin Assessment in Early-stage Breast Cancer

This study is a diagnostic open-label, prospective, single-arm non-inferiority clinical trial.

The primary endpoint is the accuracy to detect positive invasive margins in invasive ductal carcinoma (IDC) patients by high-resolution specimen Positron Emission Tomography/Computed Tomography (PET/CT) imaging.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

European Institute of Oncology

Milan, Italy

Location contact

Francesco Ceci

CONTACT

About this study

The rationale of this study is to examine the non-inferiority of intraoperative high-resolution specimen PET/CT imaging in early-stage breast cancer for the identification of all positive margins of the invasive component during Breast Cancer Surgery (BCS) as compared to standard-of-care gross pathology evaluation.

The PET/CT specimen imager is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • females with an age over 18 years;
  • confirmed breast cancer with indication to undergo BCS (stage I-II with tumor ≤2.5 in greatest dimension);
  • vacuum-assisted core breast biopsy is allowed for non-invasive tumors only;
  • able to understand treatment protocol and informed consent form;
  • estimated by the investigator to be compliant for study participation.

Exclusion criteria

  • general or local contra-indication for BCS;
  • previous breast surgery;
  • inflammatory breast cancer;
  • radiotherapy of the ipsilateral breast;
  • vacuum-assisted core breast biopsy for all patients with invasive tumors (vacuum-assisted core breast biopsy is allowed for patients with non-invasive tumors as long as the residual tumor size on mammogram is at least 1.0 cm);
  • pregnancy or lactation;
  • participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year;
  • active bacterial, viral or fungal infection.

Treatment and study plan

AURA 10 PET/CT

Device

The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard

Other names: PET/CT specimen imager (AURA 10 PET/CT)

Primary outcomes

  1. Evaluation of the accuracy to detect positive invasive margins in IDC patients

    Time frame: 1 month

    Evaluation of intraoperative high-resolution specimen PET/CT imaging for the identification of all invasive positive margins during primary breast-conserving surgery (BCS) of invasive ductal carcinoma (IDC), as compared to perioperative gross pathology evaluation. Permanent pathology is used as the gold standard for margin assessment.

Secondary outcomes

  1. Evaluation of diagnostic performance of PET/CT in the detection of positive margins respect to gross pathology

    Time frame: 1 month

    determining the diagnostic performance of intraoperative high-resolution specimen PET/CT imaging and gross pathology to detect all positive margin;

  2. Detection of malignant cells in resected lymph nodes and cavity shaves

    Time frame: 1 month

    exploring the ability of intraoperative high-resolution specimen PET/CT imaging to detect the presence of malignant cells in resected lymph nodes and cavity shaves;

  3. Definition of optimal SUVmax cut-off

    Time frame: 1 months

    determining the optimal SUVmax cut-off in intraoperative high-resolution specimen PET/CT imaging for the correct detection of malignant vs. non-malignant tissues, using pathology results as standard-of-reference

Study contacts

Contact information is provided by the study sponsor or research team.

Francesco Ceci, MD

CONTACT

[email protected]

+390257489315

Francesco Mattana

CONTACT

[email protected]

+390257489315

Sponsors and collaborators

Lead sponsor

European Institute of Oncology

Other

Registry information

Official study title

SURGYPET: Intra-SURGerY High-resolution Specimen PET/CT Imager for Margin Assessment in Early-stage Breast Cancer as Compared to Gross Pathology: a Prospective Non-inferiority Analysis

Acronym: SURGYPET

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 26, 2024
Registry last updated
Jun 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.